Microvesicles at the crossroads between infection and cardiovascular diseases

Journal of Cardiovascular Pharmacology

Volumn 59, Issue 2, 2012, Pages 124-132

  Xiong, Jing ^a,b   Miller, Virginia M ^b,c   Li, Yunman ^a   Jayachandran, Muthuvel ^c  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

^b MAYO CLINIC   (United States)

^c MAYO GRADUATE SCHOOL   (United States)

Author keywords

atherosclerosis; infection; inflammation; leukocytes; platelets

Indexed keywords

ADENOSINE DIPHOSPHATE; ADRENALIN; AUTOANTIGEN; C REACTIVE PROTEIN; CD146 ANTIGEN; CD19 ANTIGEN; CD3 ANTIGEN; CD31 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; COLLAGEN; EDETIC ACID; EGTAZIC ACID; HLA ANTIGEN CLASS 1; INTERLEUKIN 1; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MEMBRANE RECEPTOR; PROTEIN; RNA; THROMBIN; TUMOR NECROSIS FACTOR ALPHA;

APOPTOSIS; BACTERIAL INFECTION; BLOOD CLOTTING; CARDIOVASCULAR DISEASE; CELL ADHESION; CELL COMMUNICATION; CONFERENCE PAPER; CYTOKINE PRODUCTION; DISEASE COURSE; ENDOTHELIUM CELL; HUMAN; IMMUNE RESPONSE; INFECTION; INFLAMMATION; MAMMAL CELL; MEMBRANE VESICLE; METABOLIC DISORDER; MICROVESICLE; NEUTROPHIL; NONHUMAN; OXIDATIVE STRESS; POLYMORPHONUCLEAR CELL; PORPHYROMONAS GINGIVALIS; PRIORITY JOURNAL; SHEAR STRESS; SIGNAL TRANSDUCTION; THROMBOCYTE ACTIVATION; THROMBOSIS;

ANIMALS; BACTERIAL INFECTIONS; CARDIOVASCULAR DISEASES; CELL-DERIVED MICROPARTICLES; DISEASE PROGRESSION; HUMANS; INFECTION; INFLAMMATION; RISK FACTORS;

EID: 84857038877     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0b013e31820c6254     Document Type: Conference Paper

References (140)

1. Kalvegren H, Majeed M, Bengtsson T. Chlamydia pneumoniae binds to platelets and triggers P-selectin expression and aggregation: a causal role in cardiovascular disease? Arterioscler Thromb Vasc Biol. 2003;23: 1677-1683. (Pubitemid 37108216)
2. Lee N, Hui D, Wu A, et al. A major outbreak of severe acute respiratory syndrome in Hong Kong. N Engl J Med. 2003;348:1986-1994. (Pubitemid 36569987)
3. Pasceri V, Patti G, Cammarota G, et al. Virulent strains of Helicobacter pylori and vascular diseases: a meta-analysis. Am Heart J. 2006;151: 1215-1222. (Pubitemid 43866599)
4. Willershausen B, Kasaj A, Willershausen I, et al. Association between chronic dental infection and acute myocardial infarction. J Endod. 2009; 35:626-630.
5. Smeeth L, Thomas SL, Hall AJ, et al. Risk of myocardial infarction and stroke after acute infection or vaccination. N Engl J Med. 2004;351: 2611-2618. (Pubitemid 39628582)
6. Casscells SW, Granger E, Kress AM, et al. Use of oseltamivir after influenza infection is associated with reduced incidence of recurrent adverse cardiovascular outcomes among military health system beneficiaries with prior cardiovascular diseases. Circulation. 2009;2: 108-115.
7. Patel KN, Soubra SH, Lam FW, et al. Polymicrobial sepsis and endotoxemia promote microvascular thrombosis via distinct mechanisms. J Thromb Haemost. 2010;8:1403-1409.
8. Heit JA, Melton LJI, Lohse CM, et al. Incidence of venous thromboembolism in hospitalized patients vs community residents. Mayo Clin Proc. 2001;76:1102-1110.
9. Watson C, Alp NJ. Role of Chlamydia pneumoniae in atherosclerosis. Clin Sci (Lond). 2008;114:509-531. (Pubitemid 351548759)
10. Schwartz MK, Hunter LW, Huebner M, et al. Characterization of biofilm formed by human-derived nanoparticles. Nanomedicine. 2009;4: 931-941.
11. Nieuwland R, Berckmans RJ, McGregor S, et al. Cellular origin and procoagulant properties of microparticles in meningococcal sepsis. Blood. 2000;95:930-935. (Pubitemid 30063043)
12. Ogura H, Tanaka H, Ko h T, et al. Enhanced production of endothelial microparticles with increased binding to leukocytes in patients with severe systemic inflammatory response syndrome. J Trauma. 2004;56: 823-830; Discussion 830-831. (Pubitemid 38534094)
13. Larsson A, Nilsson B, Eriksson M. Thrombocytopenia and platelet microvesicle formation caused by Legionella pneumophila infection. Thromb Res. 1999;96:391-397.
14. Mallat Z, Hugel B, Ohan J, et al. Shed membrane microparticles with procoagulant potential in human atherosclerotir plaques: a role for apoptosis in plaque thrombogenicity. Circulation. 1999;99:348-353. (Pubitemid 29051259)
15. Mallat Z, Benamer H, Hugel B, et al. Elevated levels of shed membrane microparticles with procoagulant potential in the peripheral circulating blood of patients with acute coronary syndromes. Circulation. 2000;101: 841-843. (Pubitemid 30117876)
16. Piccin A, Murphy WG, Smith OP. Circulating microparticles: pathophysiology and clinical implications. Blood Rev. 2007;21:157-171. (Pubitemid 46529055)
17. Cocucci E, Racchetti G, Meldolesi J. Shedding microvesicles: artefacts no more. Trends Cell Biol. 2009;19:43-51.
18. Morel O, Toti F, Hugel B, et al. Cellular microparticles: a disseminated storage pool of bioactive vascular effectors. Curr Opin Hematol. 2004; 11:156-164. (Pubitemid 38952003)
19. Jimenez JJ, Jy W, Mauro LM, et al. Endothelial cells release phenotypically and quantitatively distinct microparticles in activation and apoptosis. Thromb Res. 2003;109:175-180. (Pubitemid 36712905)
20. Hashimoto K, Jayachandran M, Owen WG, et al. Aggregation and microparticle production through toll-like receptor 4 activation in platelets from recently menopausal women. J Cardiovasc Pharmacol. 2009;54:57-62.
21. Wu C-Y, Martel J, Young D, et al. Fetuin-A/albumin-mineral complexes resembling serum calcium granules and putative nanobacteria: demonstration of a dual inhibition-seeding concept. PLoS One. 2009;4:e8058.
22. Young JD, Martel J, Young D, et al. Characterization of granulations of calcium and apatite in serum as pleomorphic mineralo-protein complexes and as precursors of putative nanobacteria. PLoS One. 2009;4:e5421.
23. Schwartz MK, Lieske JC, Miller VM. Contribution of biologically derived nanoparticles to disease. Surgery. 2010;147:181-184.
24. Hunter LW, Shiekh FA, Pisimisis GT, et al. Key role of alkaline phosphatase in the development of human-derived nanoparticles in vitro. Acta Biomaterialia. 2011;7:1319-1345.
25. Sadallah S, Eken C, Schifferli JA. Ectosomes as modulators of inflammation and immunity. Clin Exp Immunol. 2011;163:26-32.
26. Silverman JM, Reiner NE. Exosomes and other microvesicles in infection biology: organelles with unanticipated phenotypes. Cell Microbiol. 2011;13:1-9.
27. Martinez MC, Tesse A, Zobairi F, et al. Shed membrane microparticles from circulating and vascular cells in regulating vascular function. Am J Physiol. 2005;288:H1004-H1009. (Pubitemid 40269999)
28. Joop K, Berckmans RJ, Nieuwland R, et al. Microparticles from patients with multiple organ dysfunction syndrome and sepsis support coagulation through multiple mechanisms. Thromb Haemost. 2001;85: 810-820. (Pubitemid 32421813)
29. Brogan PA, Shah V, Brachet C, et al. Endothelial and platelet microparticles in vasculitis of the young. Arthritis Rheum. 2004;50: 927-936. (Pubitemid 38331967)
30. Bernal-Mizrachi L, Jy W, Fierro C, et al. Endothelial microparticles correlate with high-risk angiographic lesions in acute coronary syndromes. Int J Cardiol. 2004;97:439-446. (Pubitemid 39550693)
31. Simak J, Gelderman MP, Yu H, et al. Circulating endothelial microparticles in acute ischemic stroke: a link to severity, lesion volume and outcome. J Thromb Haemost. 2006;4:1296-1302.
32. Amabile N, Guerin AP, Leroyer A, et al. Circulating endothelial microparticles are associated with vascular dysfunction in patients with end-stage renal failure. J Am Soc Nephrol. 2005;16:3381-3388. (Pubitemid 46179341)
33. Simak J, Gelderman MP. Cell membrane microparticles in blood and blood products: potentially pathogenic agents and diagnostic markers. Transfus Med Rev. 2006;20:1-26. (Pubitemid 41811224)
34. Horstman LL, Ahn YS. Platelet microparticles: a wide-angle perspective. Crit Rev Oncol Hematol. 1999;30:111-142. (Pubitemid 29232249)
35. Gilbert GE, Sims PJ, Wiedmer T, et al. Platelet-derived microparticles express high affinity receptors for factor VIII. J Biol Chem. 1991;266: 17261-17268. (Pubitemid 21907934)
36. Gemmell CH, Sefton MV, Yeo EL. Platelet-derived microparticle formation involves glycoprotein IIb-IIIa. Inhibition by RGDS and a Glanzmann's thrombasthenia defect. J Biol Chem. 1993;268: 14586-14589. (Pubitemid 23206590)
37. Wiedmer T, Sims PJ. Participation of protein kinases in complement C5b-9-induced shedding of platelet plasma membrane vesicles. Blood. 1991;78:2880-2886.
38. Sapet C, Simoncini S, Loriod B, et al. Thrombin-induced endothelial microparticle generation: identification of a novel pathway involving ROCK-II activation by caspase-2. Blood. 2006;108:1868-1876. (Pubitemid 44394996)
39. Miyoshi H, Umeshita K, Sakon M, et al. Calpain activation in plasma membrane bleb formation during tert-butyl hydroperoxide-induced rat hepatocyte injury. Gastroenterology. 1996;110:1897-1904. (Pubitemid 26169227)
40. Azevedo LC, Pedro M, Laurindo FR. Circulating microparticles as therapeutic targets in cardiovascular diseases. Recent Pat Cardiovasc Drug Discov. 2007;2:41-51. (Pubitemid 46813415)
41. Peterson DB, Sander T, Kaul S, et al. Comparative proteomic analysis of PAI-1 and TNF-alpha-derived endothelial microparticles. Proteomics. 2008;8:2430-2446.
42. Satta N, Toti F, Feugeas O, et al. Monocyte vesiculation is a possible mechanism for dissemination of membrane-associated procoagulant activities and adhesion molecules after stimulation by lipopolysaccharide. J Immunol. 1994;153:3245-3255. (Pubitemid 24292551)
43. Miguet L, Pacaud K, Felden C, et al. Proteomic analysis of malignant lymphocyte membrane microparticles using double ionization coverage optimization. Proteomics. 2006;6:153-171. (Pubitemid 43142942)
44. Moskovich O, Fishelson Z. Live cell imaging of outward and inward vesiculation induced by the complement c5b-9 complex. J Biol Chem. 2007;282:29977-29986. (Pubitemid 350035280)
45. Pula G, Perera S, Prokopi M, et al. Proteomic analysis of secretory proteins and vesicles in vascular research. Proteomics Clin Appl. 2008;2: 882-891. (Pubitemid 351943768)
46. Beveridge TJ, Kadurugamuwa JL. Periplasm, periplasmic spaces, and their relation to bacterial wall structure: novel secretion of selected periplasmic proteins from Pseudomonas aeruginosa. Microb Drug Resist. 1996;2:1-8. (Pubitemid 26259094)
47. Yaron S, Kolling GL, Simon L, et al. Vesicle-mediated transfer of virulence genes from Escherichia coli O157:H7 to other enteric bacteria. Appl Environ Microbiol. 2000;66:4414-4420.
48. Kadurugamuwa JL, Beveridge TJ. Membrane vesicles derived from Pseudomonas aeruginosa and Shigella flexneri can be integrated into the surfaces of other gram-negative bacteria. Microbiology. 1999;145: 2051-2060. (Pubitemid 29396935)
49. Spiewak R, Dutkiewicz J. In vitro study of pro-inflammatory and antitumour properties of microvesicles from bacterial cell wall of Pantoea agglomerans. Ann Agric Environ Med. 2008;15:153-161. (Pubitemid 351919228)
50. Kolling GL, Matthews KR. Export of virulence genes and Shiga toxin by membrane vesicles of Escherichia coli O157:H7. Appl Environ Microbiol. 1999;65:1843-1848.
51. Meyer DH, Fives-Taylor PM. Evidence that extracellular components function in adherence of Actinobacillus actinomycetemcomitans to epithelial cells. Infect Immun. 1993;61:4933-4936. (Pubitemid 23320561)
52. Renelli M, Matias V, Lo RY, et al. DNA-containing membrane vesicles of Pseudomonas aeruginosa PAO1 and their genetic transformation potential. Microbiology. 2004;150:2161-2169. (Pubitemid 39117630)
53. Vidakovics ML, Jendholm J, Morgelin M, et al. B cell activation by outer membrane vesicles-a novel virulence mechanism. PLoS pathogens. 2010;6:e1000724.
54. Pham K, Feik D, Hammond BF, et al. Aggregation of human platelets by gingipain-R from Porphyromonas gingivalis cells and membrane vesicles. Platelets. 2002;13:21-30. (Pubitemid 34169584)
55. Sharma A, Novak EK, Sojar HT, et al. Porphyromonas gingivalis platelet aggregation activity: outer membrane vesicles are potent activators of murine platelets. Oral Microbiol Immunol. 2000;15:393-396.
56. Ellis TN, Kuehn MJ. Virulence and immunomodulatory roles of bacterial outer membrane vesicles. Microbiol Mol Biol Rev. 2010;74:81-94.
57. Dutkiewicz J, Skorska C, Burrell R, et al. Immunostimulative effects of repeated inhalation exposure to microvesicle-bound endotoxin of Pantoea agglomerans. Ann Agric Environ Med. 2005;12:289-294.
58. Nunez-del AA, Salas-Tellez E, de la Garza M, et al. Identification of an immunogenic protein of Actinobacillus seminis that is present in microvesicles. Can J Vet Res. 2006;70.
59. Tashiro Y, Ichikawa S, Shimizu M, et al. Variation of physiochemical properties and cell association activity of membrane vesicles with growth phase in Pseudomonas aeruginosa. Appl Environ Microbiol. 2010;76: 3732-3739.
60. Cognasse F, Hamzeh-Cognasse H, Lafarge S, et al. Toll-like receptor 4 ligand can differentially modulate the release of cytokines by human platelets. Br J Haematol. 2008;141:84-91. (Pubitemid 351347530)
61. Kuroki Y, Tsuchida K, Go I, et al. A study of innate immunity in patients with end-stage renal disease: special reference to toll-like receptor-2 and -4 expression in peripheral blood monocytes of hemodialysis patients. Int J Mol Med. 2007;19:783-790.
62. Faure E, Equils O, Sieling PA, et al. Bacterial lipopolysaccharide activates NF-kappaB through toll-like receptor 4 (TLR-4) in cultured human dermal endothelial cells. Differential expression of TLR-4 and TLR-2 in endothelial cells. J Biol Chem. 2000;275: 11058-11063. (Pubitemid 30212746)
63. Wang JG, Manly D, Kirchhofer D, et al. Levels of microparticle tissue factor activity correlate with coagulation activation in endotoxemic mice. J Thromb Haemost. 2009;7:1092-1098.
64. Eriksson M, Nelson D, Nordgren A, et al. Increased platelet microvesicle formation is associated with mortality in a porcine model of endotoxemia. Acta Anaesthesiol Scand. 1998;42:551-557. (Pubitemid 28218477)
65. Larsson A, Eriksson M, Lundahl T, et al. Impaired platelet function in endotoxemic pigs analyzed by flow cytometry. Platelets. 1998;9: 115-119. (Pubitemid 28209822)
66. Lipcsey M, Larsson A, Olovsson M, et al. Early endotoxin-mediated haemostatic and inflammatory responses in the clopidogrel-treated pig. Platelets. 2005;16:408-414. (Pubitemid 41564338)
67. de Vos AF, Pater JM, van den Pangaart PS, et al. In vivo lipopolysaccharide exposure of human blood leukocytes induces cross-tolerance to multiple TLR ligands. J Immunol. 2009;183:533-542.
68. Jayachandran M, Miller VM, Brunn GJ, et al. Platelet response as a sentinel marker of toll-like receptor 4 activation in mice. Thromb Res. 2009; In press.
69. Jayachandran M, Brunn GJ, Karnicki K, et al. In vivo effects of lipopolysaccharide and TLR4 on platelet production and activity: Implications for thrombotic risk. J Appl Physiol. 2007;102:429-433. (Pubitemid 46089795)
70. Stahl AL, Sartz L, Nelsson A, et al. Shiga toxin and lipopolysaccharide induce platelet-leukocyte aggregates and tissue factor release, a thrombotic mechanism in hemolytic uremic syndrome. PLoS One. 2009;4: e6990.
71. Liu ML, Reilly MP, Casasanto P, et al. Cholesterol enrichment of human monocyte/macrophages induces surface exposure of phosphatidylserine and the release of biologically-active tissue factor-positive microvesicles. Arterioscler Thromb Vasc Biol. 2007;27:430-435. (Pubitemid 46143061)
72. Watanabe J, Marathe GK, Neilsen PO, et al. Endotoxins stimulate neutrophil adhesion followed by synthesis and release of plateletactivating factor in microparticles. J Biol Chem. 2003;278: 33161-33168. (Pubitemid 37055763)
73. Gauley J, Pisetsky DS. The release of microparticles by RAW 264.7 macrophage cells stimulated with TLR ligands. J Leukoc Biol. 2010;87: 1115-1123.
74. Kim SK, Kim YM, Yeum CE, et al. Rifampicin inhibits the LPS-induced Expression of Toll-like Receptor 2 via the Suppression of NF-kappaB DNA-binding Activity in RAW 264.7 Cells. Korean J Physiol Pharmacol. 2009;13:475-482.
75. Angelot F, Seilles E, Biichle S, et al. Endothelial cell-derived microparticles induce plasmacytoid dendritic cell maturation: potential implications in inflammatory diseases. Haematologica. 2009;94: 1502-1512.
76. Rauch U, Bonderman D, Bohrmann B, et al. Transfer of tissue factor from leukocytes to platelets is mediated by CD15 and tissue factor. Blood. 2000;96:170-175. (Pubitemid 30456467)
77. Martin S, Tesse A, Hugel B, et al. Shed membrane particles from T lymphocytes impair endothelial function and regulate endothelial protein expression. Circulation. 2004;109:1653-1659. (Pubitemid 38451723)
78. Distler JH, Pisetsky DS, Huber LC, et al. Microparticles as regulators of inflammation: novel players of cellular crosstalk in the rheumatic diseases. Arthritis Rheum. 2005;52:3337-3348. (Pubitemid 41612200)
79. Mesri M, Altieri DC. Endothelial cell activation by leukocyte microparticles. J Immunol. 1998;161:4382-4387. (Pubitemid 28469024)
80. Miller VM, Redfield MM, McConnell JP. Use of BNP and CRP as biomarkers in assessing cardiovascular disease: diagnosis versus risk. Curr Vasc Pharmacol. 2007;5:15-25.
81. Ridker PM, Silvertown JD. Inflammation, C-reactive protein, and atherothrombosis. J Periodontol. 2008;79:1544-1551.
82. Barichello T, Savi GD, Silva GZ, et al. Antibiotic therapy prevents, in part, the oxidative stress in the rat brain after meningitis induced by Streptococcus pneumoniae. Neurosci Lett. 2010;478:93-96.
83. Calvino FM, Parra CT. H. pylori and mitochondrial changes in epithelial cells. The role of oxidative stress. Rev Esp Enferm Dig. 2010;102:41-50.
84. Patel KD, Zimmerman GA, Prescott SM, et al. Novel leukocyte agonists are released by endothelial cells exposed to peroxide. J Biol Chem. 1992; 267:15168-15175.
85. Kamat JP, Devasagayam TP, Priyadarsini KI, et al. Reactive oxygen species mediated membrane damage induced by fullerene derivatives and its possible biological implications. Toxicology. 2000;155:55-61. (Pubitemid 32056314)
86. Misra MK, Sarwat M, Bhakuni P, et al. Oxidative stress and ischemic myocardial syndromes. Med Sci Monit. 2009;15:RA209-RA219.
87. Forstermann U. Nitric oxide and oxidative stress in vascular disease. Pflugers Arch. 2010;459:923-939.
88. Ceriello A, Motz E. Is oxidative stress the pathogenic mechanism underlying insulin resistance, diabetes, and cardiovascular disease? The common soil hypothesis revisited. Arterioscler Thromb Vasc Biol. 2004; 24:816-823. (Pubitemid 38620857)
89. Shargorodsky M, Debby O, Matas Z, et al. Effect of long-term treatment with antioxidants (vitamin C, vitamin E, coenzyme Q10 and selenium) on arterial compliance, humoral factors and inflammatory markers in patients with multiple cardiovascular risk factors. Nutr Metab. 2010; 7:55.
90. Helal O, Defoort C, Robert S, et al. Increased levels of microparticles originating from endothelial cells, platelets and erythrocytes in subjects with metabolic syndrome: relationship with oxidative stress. Nutr Metab Cardiovasc Dis. 2010; In press.
91. Jayachandran M, Preston CC, Hunter LW, et al. Loss of estrogen receptor β decreases mitochondrial energetic potential and increases thrombogenicity of platelets in aged female mice. Age. 2010;32:109-121.
92. Freikman I, Amer J, Cohen JS, et al. Oxidative stress causes membrane phospholipid rearrangement and shedding from RBC membranes-an NMR study. Biochim Biophys Acta. 2008;1778:2388-2394.
93. Vince RV, Chrismas B, Midgley AW, et al. Hypoxia mediated release of endothelial microparticles and increased association of S100A12 with circulating neutrophils. Oxid Med Cell Longev. 2009;2:2-6.
94. Rossig L, Haendeler J, Mallat Z, et al. Congestive heart failure induces endothelial cell apoptosis: protective role of carvedilol. J Am Coll Cardiol. 2000;36:2081-2089.
95. Rossig L, Hoffmann J, Hugel B, et al. Vitamin C inhibits endothelial cell apoptosis in congestive heart failure. Circulation. 2001;104:2182-2187. (Pubitemid 33043297)
96. Essayagh S, Xuereb JM, Terrisse AD, et al. Microparticles from apoptotic monocytes induce transient platelet recruitment and tissue factor expression by cultured human vascular endothelial cells via a redox-sensitive mechanism. Thromb Haemost. 2007;98:831-837. (Pubitemid 47555076)
97. Herkert O, Djordjevic T, BelAiba RS, et al. Insights into the redox control of blood coagulation: role of vascular NADPH oxidase-derived reactive oxygen species in the thrombogenic cycle. Antioxid Redox Signal. 2004;6:765-776. (Pubitemid 38890794)
98. Wesche-Soldato DE, Swan RZ, Chung CS, et al. The apoptotic pathway as a therapeutic target in sepsis. Curr Drug Targets. 2007;8:493-500. (Pubitemid 46672616)
99. Abid Hussein MN, Boing AN, Sturk A, et al. Inhibition of microparticle release triggers endothelial cell apoptosis and detachment. Thromb Haemost. 2007;98:1096-1107. (Pubitemid 350107696)
100. Yu JL, May L, Lhotak V, et al. Oncogenic events regulate tissue factor expression in colorectal cancer cells: implications for tumor progression and angiogenesis. Blood. 2005;105:1734-1741. (Pubitemid 40223697)
101. van Doormaal FF, Kleinjan A, Di Nisio M, et al. Cell-derived microvesicles and cancer. Neth J Med. 2009;67:266-273.
102. Boing AN, Hau CM, Sturk A, et al. Platelet microparticles contain active caspase 3. Platelets. 2008;19:96-103. (Pubitemid 351302378)
103. Libby P. Inflammation in atherosclerosis. Nature. 2002;420:868-874. (Pubitemid 36019640)
104. Kiechl S, Egger G, Mayr M, et al. Chronic infections and the risk of carotid atherosclerosis. Prospective results from a large population study. Circulation. 2001;103:1064-1070. (Pubitemid 32200178)
105. Weerheim AM, Kolb AM, Sturk A, et al. Phospholipid composition of cell-derived microparticles determined by one-dimensional high-performance thin-layer chromatography. Anal Biochem. 2002;302:191-198. (Pubitemid 34229723)
106. Jayachandran M, Litwiller RD, Owen WG, et al. Characterization of blood borne microparticles as markers of premature coronary calcification in newly menopausal women. Am J Physiol Heart Circ Physiol. 2008;295:931-938.
107. Miller VM, Jayachandran M, Hashimoto K, et al. Estrogen, inflammation, and platelet phenotype. Gend Med. 2008;5:S91-S102. (Pubitemid 351455234)
108. Morel O, Toti F, Hugel B, et al. Procoagulant microparticles: disrupting the vascular homeostasis equation? Arterioscler Thromb Vasc Biol. 2006; 26:2594-2604.
109. Bouchard BA, Mann KG, Butenas S. No evidence for tissue factor on platelets. Blood. 2010;166:854-855.
110. Muller I, Klocke A, Alex M, et al. Intravascular tissue factor initiates coagulation via circulating microvesicles and platelets. FASEB J. 2003; 17:476-478.
111. Panes O, Matus V, Saez CG, et al. Human platelets synthesize and express functional tissue factor. Blood. 2007;109:5242-5250. (Pubitemid 46890544)
112. Key NS. Platelet tissue factor: how did it get there and is it important? Semin Hematol. 2008;45(2 suppl 1):S16-S20. (Pubitemid 351787684)
113. Falati S, Liu Q, Gross P, et al. Accumulation of tissue factor into developing thrombi in vivo is dependent upon microparticle P-selectin glycoprotein ligand 1 and platelet P-selectin. J Exp Med. 2003;197: 1585-1598. (Pubitemid 36682554)
114. Collen D, Hoylaerts MF. Relationship betwen inflammation and venous thromboembolism as studied by microparticle assessment in plasma. J Am Coll Cardiol. 2005;45:1472-1473. (Pubitemid 40615621)
115. Furie B, Furie BC. Role of platelet P-selectin and microparticle PSGL-1 in thrombus formation. Trends Mol Med. 2004;10:171-178. (Pubitemid 38410975)
116. Del Conde I, Shrimpton CN, Thiagarajan P, et al. Tissue-factor-bearing microvesicles arise from lipid rafts and fuse with activated platelets to initiate coagulation. Blood. 2005;106:1604-1611. (Pubitemid 41208572)
117. Bach R, Rifkin DB. Expression of tissue factor procoagulant activity: regulation by cytosolic calcium. Proc Natl Acad Sci U S A. 1990;87: 6995-6999.
118. Butenas S, Bouchard BA, Brummel-Ziedins KE, et al. Tissue factor activity in whole blood. Blood. 2005;105:2764-2770. (Pubitemid 40446267)
119. Giesen PLA, Rauch U, Bohrmann B, et al. Blood-borne tissue factor: Another view of thrombosis. Proc Natl Acad Sci U S A. 1999;96: 2311-2315. (Pubitemid 29117911)
120. Boulanger CM, Scoazec A, Ebrahimian T, et al. Circulating microparticles from patients with myocardial infarction cause endothelial dysfunction. Circulation. 2001;104:2649-2652. (Pubitemid 33108128)
121. Agouni A, Lagrue-Lak-Hal AH, Ducluzeau PH, et al. Endothelial dysfunction caused by circulating microparticles from patients with metabolic syndrome. Am J Pathol. 2008;173:1210-1219.
122. Tesse A, Martinez MC, Hugel B, et al. Upregulation of proinflammatory proteins through NF-kappaB pathway by shed membrane microparticles results in vascular hyporeactivity. Arterioscler Thromb Vasc Biol. 2005; 25:2522-2527. (Pubitemid 43732273)
123. Forlow SB, McEver RP, Nollert MU. Leukocyte-leukocyte interactions mediated by platelet microparticles under flow. Blood. 2000;95:1317-1323. (Pubitemid 30099841)
124. Barry OP, Pratico D, Savani RC, et al. Modulation of monocyteendothelial cell interactions by platelet microparticles. J Clin Invest. 1998;102:136-144. (Pubitemid 28323840)
125. Libby P, Theroux P. Pathophysiology of coronary artery disease. Circulation. 2005;111:3481-3488. (Pubitemid 40923403)
126. Ludwig RJ, Schultz JE, Boehncke WH, et al. Activated, not resting, platelets increase leukocyte rolling in murine skin utilizing a distinct set of adhesion molecules. J Invest Dermatol. 2004;122:830-836. (Pubitemid 38471355)
127. Sabatier F, Roux V, Anfosso F, et al. Interaction of endothelial microparticles with monocytic cells in vitro induces tissue factordependent procoagulant activity. Blood. 2002;99:3962-3970. (Pubitemid 35332035)
128. Kiechl S, Lorenz E, Reindl M, et al. Toll-like receptor 4 polymorphisms and atherogenesis. N Engl J Med. 2002;347:185-192. (Pubitemid 34764822)
129. De Kleijn D, Pasterkamp G. Toll-like receptors in cardiovascular diseases. Cardiovasc Res. 2003;60:58-67. (Pubitemid 38373476)
130. Bucova M, Bernadic M, Buckingham T. C-reactive protein, cytokines and inflammation in cardiovascular diseases. Bratisl Lek Listy. 2008;109: 333-340.
131. MacKenzie A, Wilson HL, Kiss-Toth E, et al. Rapid secretion of interleukin-1beta by microvesicle shedding. Immunity. 2001;15: 825-835. (Pubitemid 34008509)
132. Hart DN. Dendritic cells: unique leukocyte populations which control the primary immune response. Blood. 1997;90:3245-3287. (Pubitemid 27473395)
133. Kaneider NC, Kaser A, Tilg H, et al. CD40 ligand-dependent maturation of human monocyte-derived dendritic cells by activated platelets. Int J Immunopathol Pharmacol. 2003;16:225-231. (Pubitemid 39011228)
134. Sprague DL, Elzey BD, Crist SA, et al. Platelet-mediated modulation of adaptive immunity: unique delivery of CD154 signal by platelet-derived membrane vesicles. Blood. 2008;111:5028-5036.
135. Epstein SE, Zhu J, Burnett MS, et al. Infection and atherosclerosis: potential roles of pathogen burden and molecular mimicry. ArteriosclerThromb Vasc Biol. 2000;20:1417-1420. (Pubitemid 30353867)
136. Zhu J, Nieto FJ, Horne BD, et al. Prospective study of pathogen burden and risk of myocardial infarction or death. Circulation. 2001;103:45-51. (Pubitemid 32050434)
137. Espinola-Klein C, Rupprecht HJ, Blankenberg S, et al. Impact of infectious burden on progression of carotid atherosclerosis. Stroke. 2002; 33:2581-2586. (Pubitemid 35266427)
138. Jayachandran M, Litwiller RD, Owen WG, et al. Circulating microparticles and endogenous estrogen in newly menopausal women. Climacteric. 2009;12:177-184.
139. Denti L. The hormone replacement therapy (HRT) of menopause: focus on cardiovascular implications. Acta Biomed. 2010;81(suppl 1):73-76.
140. Bittner V. Menopause, age, and cardiovascular risk: a complex relationship. J Am Coll Cardiol. 2009;54:2374-2375